Literature DB >> 2655274

Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins.

C S Schmaljohn1, M D Parker, W H Ennis, J M Dalrymple, M S Collett, J A Suzich, A L Schmaljohn.   

Abstract

Autographa californica nuclear polyhedrosis viral recombinants containing coding information for the Rift Valley fever virus (RVFV) envelope glycoproteins (G1 and G2) and varying amounts of preglycoprotein coding sequences were prepared by using transfer vectors pAc373 or pAcYM1. Expression products were processed to yield proteins indistinguishable from authentic G1 and G2 by gel electrophoresis. The immunogenic properties of the expressed proteins were assessed by immunizing mice and challenging with RVFV. A single inoculation with lysates of cells infected with recombinants expressing both G1 and G2 induced neutralizing antibody responses in mice and protected them from an otherwise lethal challenge with RVFV. Lysates of cells infected with a recombinant expressing only G2 also induced a protective response after two immunizations. Survivors displayed elevated antibody titers to G1 and G2 and also developed antibodies to the RVFV nucleocapsid protein, the latter allowing discrimination from vaccinated mice and indicating that animals had survived infection. Nonimmune mice were protected from lethal RVFV infection by passive transfer of sera from animals immunized with recombinant antigens, indicating that a humoral immune response is sufficient to protect against RVFV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655274     DOI: 10.1016/0042-6822(89)90365-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  NSm and 78-kilodalton proteins of Rift Valley fever virus are nonessential for viral replication in cell culture.

Authors:  Sungyong Won; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

3.  The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins.

Authors:  T G Besselaar; N K Blackburn
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants.

Authors:  C S Schmaljohn; Y K Chu; A L Schmaljohn; J M Dalrymple
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.

Authors:  David H Holman; Adam Penn-Nicholson; Danher Wang; Jan Woraratanadharm; Mary-Katherine Harr; Min Luo; Ellen M Maher; Michael R Holbrook; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 6.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

Review 7.  Rift valley fever vaccines.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

9.  Rapid accumulation of virulent rift valley Fever virus in mice from an attenuated virus carrying a single nucleotide substitution in the m RNA.

Authors:  John C Morrill; Tetsuro Ikegami; Naoko Yoshikawa-Iwata; Nandadeva Lokugamage; Sungyong Won; Kaori Terasaki; Aya Zamoto-Niikura; C J Peters; Shinji Makino
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

10.  A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge.

Authors:  Robert B Mandell; Ramesh Koukuntla; Laura J K Mogler; Andrea K Carzoli; Alexander N Freiberg; Michael R Holbrook; Brian K Martin; William R Staplin; Nicholas N Vahanian; Charles J Link; Ramon Flick
Journal:  Virology       Date:  2009-11-24       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.